Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Grifols SA ( (GRFS) ) just unveiled an update.
On March 24, 2026, Grifols announced that its board has begun evaluating a potential U.S. initial public offering of a portion of the shares of its subsidiary that heads its U.S. Biopharma business, as part of its self-sufficiency programs for plasma-derived medicines. The company stressed that the IPO is only under consideration, subject to regulatory approvals and market conditions, and emphasized that Grifols’ shares will continue to trade in Spain regardless of whether the transaction proceeds.
The move signals a possible restructuring of how Grifols finances and organizes its U.S. Biopharma operations, which could sharpen its strategic focus on key plasma-therapy markets. While the outcome remains uncertain, any eventual listing of the U.S. unit could affect capital structure, investor access to the business, and Grifols’ positioning in the competitive biopharmaceutical sector.
The most recent analyst rating on (GRFS) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.
Spark’s Take on GRFS Stock
According to Spark, TipRanks’ AI Analyst, GRFS is a Neutral.
GRFS scores moderately: improving cash flow and a constructive earnings-call outlook (including better free cash flow and deleveraging progress) are the main positives. These are tempered by still-elevated leverage and thin profitability, while technical signals remain slightly negative and valuation is only moderately supportive.
To see Spark’s full report on GRFS stock, click here.
More about Grifols SA
Grifols S.A., based in Barcelona, is a global biopharmaceutical company specializing in plasma-derived medicines and other biopharma products. The group has a significant U.S. Biopharma business and focuses on achieving territorial self-sufficiency in the supply of plasma-derived therapies, aiming to ensure reliable access to these medicines in key markets.
Average Trading Volume: 619,319
Technical Sentiment Signal: Sell
Current Market Cap: $6.28B
See more insights into GRFS stock on TipRanks’ Stock Analysis page.